Characteristics of the 47 patients treated with imatinib mesylate and the 133 historical control patients treated with cytarabine-containing regimens (1972-2000) for frontline therapy of myeloid blast-phase chronic myelogenous leukemia
| Characteristic . | Treatment, % . | |
|---|---|---|
| Imatinib mesylate . | Cytarabine regimens . | |
| Age > 60 years (median) | 47 (57) | 20 (45) |
| Splenomegaly > 5 cm bcm | 36 | 32 |
| Hemoglobin < 10 g/dL | 43 | 52 |
| WBC > 50 × 109/L | 28 | 31 |
| Peripheral blasts > 30% | 74 | 66 |
| Marrow blasts > 50% | 47 | 42 |
| Time from diagnosis to blastic phase ≥ 36 mo | 53 | 42 |
| Characteristic . | Treatment, % . | |
|---|---|---|
| Imatinib mesylate . | Cytarabine regimens . | |
| Age > 60 years (median) | 47 (57) | 20 (45) |
| Splenomegaly > 5 cm bcm | 36 | 32 |
| Hemoglobin < 10 g/dL | 43 | 52 |
| WBC > 50 × 109/L | 28 | 31 |
| Peripheral blasts > 30% | 74 | 66 |
| Marrow blasts > 50% | 47 | 42 |
| Time from diagnosis to blastic phase ≥ 36 mo | 53 | 42 |
bcm indicates below costal margin; WBC, white blood count.